Author name: admin

BRISBANE, Australia–(BUSINESS WIRE)–May 21, 2014– First Solar, Inc. (NASDAQ: FSLR), Rio Tinto and Ingenero today announced that agreement has been reached for the development of the Weipa Solar Photovoltaic (PV) Project in Queensland, Australia. The project has received official confirmation of funding from the Commonwealth Government, with an initial commitment of $3.5 million from the Australian Renewable Energy Agency (ARENA) to be followed by an allocation of up to $7.8 million for the project’s second phase. First Solar will leverage its expertise in utility-scale grid integration and plant control systems to offer a FuelSmart solution that provides maximum fuel savings while maintaining system reliability. Combined with Ingenero’s proven design, development […]

Datacastle RED now available via IBM Cloud Marketplace SEATTLE, Apr 28, 2014 — Datacastle today announced a partnership with IBM that brings the power of Datacastle RED to the IBM Cloud marketplace. Starting today, IBM clients can quickly and easily procure Datacastle’s industry leading enterprise endpoint backup and recovery solution hosted on IBM SoftLayer. Datacastle RED transforms vulnerable mobile workforce data into resilient endpoint data. Datacastle RED uniquely provides highly performant and secure hybrid cloud backup and recovery with QuickCache™ running on NAS devices deployed at remote offices, home offices, or the corporate LAN. Coupled with Datacastle’s advanced RoamSmart™ technology, security suite, and enterprise integration APIs (AD/LDAP/SAML), Datacastle RED is recognized as the industry leader in

Sunshine Heart Appoints Kimberly Oleson as Senior Vice President, Clinical Affairs EDEN PRAIRIE, Minn., April 28, 2014 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) today announced the appointment of Kimberly Oleson to the post of Senior Vice President, Clinical Affairs. In this capacity, Ms. Oleson will manage all aspects of the Company’s US pivotal study (COUNTER HF™) and EU post-market study (OPTIONS HF) for its flagship C-Pulse® Heart Assist System, a medical device addressing Class III and ambulatory Class IV heart failure. “Kim brings to the Company deep expertise across all aspects of medical device trial enrollment and management. Having been involved with over 400 clinical trials in her career, it

Company Reveals Aggressive Plans to Expand the Largest Shared Global Identity Network San Jose, Calif. – March 27, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announced that it has closed a Series E round of financing. Adams Street Partners led the investment round of $20 million in capital, with all existing ThreatMetrix institutional investors also participating in the investment. In a 12-month period ending September 2013, investors poured more than$1.4 billion into the cybersecurity market, up 29 percent over the previous year. While many cybersecurity startups are in the early stages of business, ThreatMetrix has a proven business strategy and is uniquely positioned to protect online

ThreatMetrix Augments Mobile Solution with Jailbreak Detection and Location-Based Authentication San Jose, Calif. – March 13, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announced the upcoming availability of the ThreatMetrix™ Spring 2014 Release, an extension to the company’s TrustDefender™ Cybercrime Protection Platform. This update delivers enhanced endpoint and context intelligence for mobile activity through a solution built on the ThreatMetrix™ Global Trust Intelligence Network (The Network). Mobile devices represent an increasing number of transactions and account logins from consumers and across the workforce. In 2013, mobile represented one third of total traffic on The Network and this number is projected to reach 50 percent by the end

  Award Winners and Finalists Were Honored by Info Security Products Guide in San Francisco during the RSA Conference 2014 on February 24 San Jose, Calif. – February 27, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announces that Info Security Products Guide, the industry’s leading information security research and advisory guide, named the company a Bronze winner of the 2014 Global Excellence Awards for Most Innovative Company of the Year (Security). The security industry celebrated its 10th Annual 2014 Global Excellence Awards during the RSA Conference 2014 in San Francisco by honoring excellence in every facet of the industry, including companies, executives and

Context-Based Security and Advanced Fraud Prevention Provider Recognized for its Continuous Efforts to Build Trust on the Internet Leveraging the World’s Largest Trusted Identity Network San Jose, Calif. – February 24, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announces it has been honored in two categories by the Cyber Defense Magazine Awards, including Most Innovative Anti-Malware Appliances Solution and Best Product Network Access Control Solution. The Cyber Defense Magazine Awards recognize the top IT security leaders who strive to curate cutting-edge knowledge on cybercrime and create advanced solutions to solve the online security issues facing businesses today. The awards were announced during the RSA Conference

Real-Time Identity Analytics and Federated Trust Combine Security, Low Total Cost of Ownership and Optimal User Experience San Jose, Calif. – February 20, 2014 – ThreatMetrix™, the fastest-growing provider of context-based security and advanced fraud prevention solutions, today announced a revolutionary offering that improves the security associated with traditional username and password protection for accessing enterprise applications in conjunction with the upcoming RSA Conference 2014, February 24-28 at Moscone Center, San Francisco. With the advent of bring-your-own-device (BYOD) and cloud-based applications, today’s enterprise security professionals are challenged with augmenting the application access security that can be obtained through simple username and password verification and cumbersome two-factor authentication with minimal impact to the

ThreatMetrix Leads the Industry in “Building Trust on the Internet” to Reduce Fraud and Facilitate Fast and Frictionless Online Transactions San Jose, CA – January 29, 2014 – ThreatMetrix™, the fastest growing provider of context-based authentication and advanced Web fraud prevention solutions, today announced a compilation of record 2013 milestones and its emergence as one of the largest fully anonymized global identity and fraud networks in the world. In 2013, the rules governing global cybercrime protection changed. Global governments now assign more importance to individual consumer privacy than to the rapidly increasing financial losses online retailers, enterprises and financial institutions face at the hands of highly sophisticated global cybercriminals. “We work

Minnesota, United States and Melbourne, Australia – January 7, 2014 – Osprey Medical Inc. (ASX: OSP) today announced enrollment of the first patient in the AVERT IDE Clinical Study. The patient was enrolled at Harbor UCLA Medical Center in Torrance, California by Dr William French. This trial will evaluate the Company’s AVERT™ System for a marketing claim expansion to include “reduction of Contrast Induced Nephropathy (CIN)” for patients undergoing angiogram or stenting procedures. The randomized, multi-center, IDE trial will be enrolling approximately 700 patients at up to 45 sites in the U.S., Canada, Europe, Australia, and New Zealand. In addition to evaluating the effectiveness of the AVERT System for CIN

Minnesota, United States and Melbourne, Australia – January 2, 2014 – Osprey Medical Inc. (ASX: OSP) today announced publication of results from the pilot clinical trial of the AVERT system (Contrast Conservation System/CCS). The study which was conducted in late 2012 at the Alfred Hospital in Melbourne Australia by Dr David Kaye and Dr Stephen Duffy, was titled “Reducing iodinated contrast volume by manipulating injection pressure during coronary angiography” and was published ahead of press on-line in the December 2013 edition of leading industry peer-reviewed journal “Catheterization and Cardiovascular Interventions”. The 21-patient pilot clinical trial, demonstrated that the use of the AVERT System was associated with a highly significant 40%

Minnesota, United States and Melbourne, Australia – January 2, 2014 – Osprey Medical Inc. (ASX: OSP) today announced publication of results from the pilot clinical trial of the AVERT system (Contrast Conservation System/CCS). The study which was conducted in late 2012 at the Alfred Hospital in Melbourne Australia by Dr David Kaye and Dr Stephen Duffy, was titled “Reducing iodinated contrast volume by manipulating injection pressure during coronary angiography” and was published ahead of press on-line in the December 2013 edition of leading industry peer-reviewed journal “Catheterization and Cardiovascular Interventions”. The 21-patient pilot clinical trial, demonstrated that the use of the AVERT System was associated with a highly significant 40%

Greensboro, NC November 18, 2013 – In June the US Food and Drug Administration’s Center for Veterinary Medicine approved the first application of Piedmont Pharmaceuticals’ invention of a soft chew formulation containing a veterinary medicine. This flavored soft chew formulation contains carprofen and is labeled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category. Beyond the Animal Health sector this soft chew formulation is patented for use in delivering human pharmaceutical medications orally. Piedmont has demonstrated positive data supporting the use of two common OTC medications in

Minnesota, United States and Melbourne, Australia – November 18, 2013 – Osprey Medical Inc. (ASX: OSP) today announced that Dr. Roxana Mehran will be the Principal Investigator (PI) of the AVERT Trial. This trial will evaluate the Company’s AVERT™ System for a marketing claim expansion to include “reduction of Contrast Induced Nephropathy (CIN)” for patients undergoing angiogram or stenting procedures. The randomized, multi-center, IDE trial will be enrolling approximately 700 patients at up to 45 sites in the U.S., Canada, Europe, Australia, and New Zealand. Dr Mehran is a U.S. interventional cardiologist with world-recognized expertise in the area of CIN. She is Professor of Medicine and Director of Interventional Cardiovascular

EDEN PRAIRIE, Minn., Oct. 29, 2013 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today that the initial C-Pulse® System patient data of its ongoing OPTIONS HF EU trial, will be presented by Professor Thomas Krabatsch, Director of Mechanical Circulatory Support at the German Heart Institute, Berlin to the investment community at Sunshine Heart’s third annual analyst breakfast event, held this morning at 7:30 a.m. PDT at the W Hotel San Francisco. As announced on October 22, 2013, the event also includes presentations from Dr. Andrew Kao, Associate Professor of Medicine at the University of Missouri-Kansas City; as well as Dr. William Cohn, Director of Minimally Invasive Surgical Technology of

Minnesota, United States and Melbourne, Australia – October 22, 2013 – Osprey Medical Inc. (ASX: OSP) today announced the first patient enrolment in its Limb Recovery™ System efficacy study. This technology allows clinicians to use existing antibiotic therapy in a more targeted and aggressive way in patients with diabetes who present with life or limb threatening foot infections. The patient was enroled at the Royal Melbourne Hospital in Melbourne, Australia. Osprey’s efficacy study will involve a 20 patient randomized clinical trial comparing the effectiveness of Osprey’s percutaneous perfusion Limb Recovery System with standard intravenous delivery of antibiotic therapy for treatment of severe limb infections. The system enables the circulation of

Brings enterprise-grade endpoint data protection to public sync and share services SEATTLE, October 1st, 2013 – Datacastle®, a market leader for protecting enterprises from endpoint data loss and data breaches, today announced that its flagship product, Datacastle RED™  now supports secure backup and restore of company data when using major cloud sync and share services such as DropBox, Microsoft SkyDrive, Box, Google Drive, and Amazon Cloud Drive. This new capability is added to Datacastle’s recognized QuickCache™ and RoamSmart™ technologies that support intelligent backup and recovery roaming across hybrid cloud deployments with mobile broadband detection functionality. “While many vendors in the enterprise IT sector are trying to provide companies with a “rip and replace” alternative to these

EDEN PRAIRIE, Minn., Sept. 24, 2013 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today the closing of its previously announced underwritten public offering of 4,381,500 shares of its common stock, which includes the full overallotment of 571,500 shares, at a price to the public of $10.50 per share. The net proceeds from the sale of shares by Sunshine Heart, after underwriting discounts and other offering expenses, total approximately $42.6 million. Piper Jaffray & Co. and Cowen and Company, LLC acted as joint book-running managers and Lazard Capital Markets LLC acted as co-lead manager for the offering. Craig-Hallum Capital Group and Northland Securities, Inc. acted as co-managers for the offering.

September 23rd 2013, Reading, Berkshire: Mesaplexx announces that the company and its xCube technology have been shortlisted for two prestigious industry awards in the past fortnight. Mesaplexx has been shortlisted as a potential ‘Innovator of the Year’ in the Growing Business Awards, the most widely supported national awards program, recognising successful UK SMEs and entrepreneurs. Backed by Lloyds Bank, The CBI and RealBusiness Magazine, the awards have celebrated successful British businesses for the past 15 years. Mesaplexx’s xCube technology has also been nominated to receive a Global Business Excellence Award for Outstanding Innovation, an awards program that recognises and rewards business excellence in all sectors. The patented xCube range of filters

EDEN PRAIRIE, Minn., Sept. 12, 2013 (GLOBE NEWSWIRE) — Sunshine Heart, Inc. (Nasdaq:SSH) announced today the first patient implant in the Company’s U.S. pivotal trial, COUNTER HF. The COUNTER HF study is a prospective, randomized, multicenter, controlled trial that will evaluate the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure. Integral to the COUNTER HF study is the assessment of C-Pulse’s unique balloon counterpulsation treatment designed to improve heart function and reduce re-hospitalizations due to worsening heart failure. “We are excited to be part of this innovative clinical trial,” said cardiothoracic surgeon, Sanjeev Aggarwal, M.D., Director of Mechanical

Eden Prairie, MN: August 27, 2013: Sunshine Heart, Inc. (NASDAQ: SSH) announced that, effective today, Patrick Verta, MD, has joined the Company as Chief Medical Officer. Dr. Verta brings over 20 years of experience in the medical field with the majority of time spent in the cardiovascular field. Prior to joining Sunshine Heart, Dr. Verta served as Chief Medical Officer and Vice President of Clinical Affairs at Neomend, a medical device company that developed and commercialized the only FDA-approved sealant for air leaks following lung surgery via open thoracotomy. The company was acquired by Bard/Davol in October 2012. Before Neomend, he served as Medical Director of Clinical Research and Business

Datacastle brings enterprise-grade endpoint data protection to the IBM SmartCloud SEATTLE, June 25th, 2013 – Datacastle®, a market leader for protecting enterprises from endpoint data loss and data breaches, today announced that its flagship product, Datacastle RED is now certified for the IBM SmartCloud and available worldwide through the IBM Partner Network. Through the partnership both IBM and Datacastle customers will be able to adopt a robust cloud architecture and service model without having to make traditional investments in enterprise IT to support endpoint backup and security. Customers will benefit from IBM’s geographic footprint and security investments as well as the company’s experience as a global service provider. “Endpoint backup and recovery have become increasingly important

Greensboro, NC. Last week the US Food and Drug Administration’s Center for Veterinary Medicine approved the first application of Piedmont Pharmaceuticals’ invention of a canine soft chew formulation containing a veterinary medicine. This flavored soft chew formulation contains carprofen and is labelled for the relief of pain and inflammation from osteoarthritis and the control of post-operative pain in dogs. It is the first and only flavored, soft and chewable medicine in the pain category. The soft chew formulation will provide pet owners with a convenient and friendly way to medicate dogs. According to Roland Johnson, Chairman and CEO of Piedmont Pharmaceuticals, “The veterinary pharmaceutical industry has been working on a

June 4th 2013, Small Cells World Summit, London: Mesaplexx announces that xCube 1800 MHz filter reference designs for active antennas, small cells and compact radio systems are now in commercial deployment. The xCube range of filters and duplexers from Mesaplexx offer mobile network vendors high power handling, low insertion loss and high isolation in a light, compact, cool-running format. Mesaplexx’s patented xCube filter technology uses multimode resonators with optimized performance-enhancing coupling techniques, to deliver performance characteristics associated with far bigger and heavier duplexers. This makes them ideal for carrier-grade small cell deployments and active antennas, which demand high performance in a small, compact and lightweight package. The xCube 1800 MHz duplexer

Datacastle introduces groundbreaking RoamSmart™ technology for protecting mobile workforce data worldwide. SEATTLE, March 27, 2013 – Datacastle®, a market leader for protecting enterprises from endpoint data loss and data breaches, today announced the release of the latest version of its flagship product, Datacastle RED. Datacastle RED v6 introduces RoamSmart™ technology for providing network-optimized data protection for increasingly distributed and mobile workforces. Datacastle’s RoamSmart™ technology enables IT managers to provide a friction-free end user experience while meeting organizational security and compliance requirements worldwide. Datacastle’s RoamSmart™ technology includes: LTE, 4G, and 3G mobile broadband detection and backup policy enforcement Intelligent roaming between cloud-based vaults and QuickCaches located on corporate LAN’s or remote offices accelerating time

  AdGent Digital CEO, Cam Yuill, offers his thoughts to Skip Brand (CEO, Martini Media) on the advertising and branding opportunities made possible by the rapid increase of content consumption on tablet devices. http://www.mediapost.com/publications/article/195367/real-time-branding-rich-media-and-the-tablet.html?edition=57643#axzz2NHbHdjBz And Cam writes further on the effects of new streaming channels and the effectiveness and measurement of advertising through those channels. http://pandodaily.com/2013/03/12/nielsens-evolution-and-the-coming-of-the-ad-buy-structure-shake-up/

Mobile World Congress is, for many in the mobile community, a pivotal point in the business calendar.  There are always a number of dominant themes at the show and this year Small Cells, in all their various guises, stepped up into the mainstream. Mesaplexx, a pioneer and innovator in radio filter technology, has created a great summary of the Small Cell landscape and the technology implications that help mobile operators avoid the ever-present capacity crunch.  If you’re interested in understanding this landscape, take a look at the white paper on Mesaplexx web site titled “Active Antennas and Small Cells – Why Filters Matter”.  Highly recommended.

Datacastle Corporation Vice President, Phil Evans, shares his thoughts on the challenges of selecting a cloud provider, and most importantly on the key consideration of security policy. http://www.techbubbles.co.uk/blog/the-buck-stops-with-you-advice-when-selecting-a-cloud-provider/#more-2994

  AdGent Digital CEO offers his thoughts on live streaming of the Super Bowl to tablet devices…. http://venturebeat.com/2013/02/04/cbs-super-bowl-stream/ ….and joins a panel of ad industry experts to critique the 2013 class of Super Bowl ads http://www.hlntv.com/article/2013/02/04/super-bowl-commercials-best-worst-panel-reviews

Brisbane, QLD, Australia, 25th January 2013 – Mesaplexx is pleased to announce that the Australian office, previously sited at Eight Mile Plains, has moved to a new location in Brisbane’s West End district. The office, home to much of Mesaplexx’s intense research and development has moved to enable the set up of a new, dedicated R&D zone, to keep pace with the company’s rapid innovations and aggressive development plans. Brisbane’s West End district, in the city suburbs, is one of the city’s oldest districts, close to both the University of Queensland and Griffith University, which, along with a strong café culture, brings a diverse and exciting buzz to the area. In